| abstract |
The invention relates to the use of interferon, preferably interferon alpha in the treatment of amyotrophic lateral sclerosis (ALS), particularly in the treatment of ALS caused by a mutation in NEK1 gene. The invention also relates to a method of treating a patient afflicted by ALS comprising the steps of; (a) selecting a patient carrying a NEK1 variant, i.e. a mutation in NEK1, (b) administering a therapeutically effective amount of interferon, preferably interferon alpha, to the patient. |